StockData
Sinovac Biotech Ltd logo

Sinovac Biotech Ltd (SVA) shareholders

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 7/30
$6.47+0.00 (0.00%)

Close on Nov 16, 2026Market cap $464.94MP/E –Yield 850.08%

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
14.6%
10M of 72M shares
Institutional holders
29
4 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
1Globe Biomedical (Hong Kong) Company Limited
Joint filing with 1Globe Capital LLC (32.30%)
18,515,31532.30%13D (active) amendmentJul 7, 2025
1Globe Capital LLC
Joint filing with 1Globe Biomedical (Hong Kong) Company Limited (32.30%), Jiaqiang Li (32.30%)
18,515,31532.30%13D (active) amendmentSep 10, 2025
Saif Iv Gp L.P.
Joint filing with SAIF Partners IV L.P. (15.00%), SAIF IV GP Capital Ltd. (15.00%)
10,780,82015.00%13D (active) amendmentFeb 18, 2025
SAIF IV GP Capital Ltd.
Joint filing with SAIF Partners IV L.P. (15.00%), Saif Iv Gp, L.P. (15.00%)
10,780,82015.00%13D (active) amendmentDec 15, 2025
Saif Iv Gp, L.P.
Joint filing with SAIF Partners IV L.P. (15.00%), SAIF IV GP Capital Ltd. (15.00%)
10,780,82015.00%13D (active) amendmentJul 10, 2025
SAIF Partners IV L.P.
Joint filing with Saif Iv Gp, L.P. (15.00%), SAIF IV GP Capital Ltd. (15.00%)
10,780,82015.00%13D (active) amendmentJun 16, 2025
Weidong Yin6,359,5008.85%13D (active) amendmentJul 10, 2025
Advantech Capital Partners Ltd.
Joint filing with Advantech Capital L.P. (8.14%), Green Vision Partners Limited (8.14%) and 1 more
5,851,4238.14%13D (active) amendmentJul 8, 2025
Vivo Capital IX, LLC4,541,7646.30%13D (active) amendmentJul 11, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SVAValueChange% of portfolio
Vivo Capital, LLC5,903,0008.21%$38.19M–3.49%
Orbimed Advisors LLC2,718,7353.78%$184.47M–3.42%
Renaissance Technologies LLC1,312,5201.83%$0–0.00%
Neumann Advisory Hong Kong Ltd315,5860.44%$2.04M–0.57%
California Public Employees Retirement System68,7320.10%$0–0.00%
Skandinaviska Enskilda Banken AB (publ)40,0000.06%$0−40,0000.00%
Spark Investment Management LLC29,1000.04%$0–0.00%
Geode Capital Management, LLC27,7170.04%$0–0.00%
Susquehanna International Group, Llp16,4300.02%$106.30K–0.00%
Navellier & Associates Inc13,0180.02%$0New0.00%
Morgan Stanley9,1460.01%$59.17K+20.00%
Wells Fargo & Company/Mn4,5800.01%$29.63K−2310.00%
UBS Group AG2,4790.00%$16.04K+2500.00%
Osaic Holdings, Inc.1,0010.00%$0−1,2000.00%
Atlantic Edge Private Wealth Management, LLC1,0000.00%$0–0.00%
Northwestern Mutual Wealth Management Co1,0000.00%$0–0.00%
Clearstead Advisors, LLC5000.00%$0–0.00%
Royal Bank of Canada4260.00%$0–0.00%
Tower Research Capital LLC (TRC)4240.00%$0–0.00%
Integrated Wealth Concepts LLC3660.00%$0New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20262910M14.6%4 / 35 / 20M0M
Q1 20262810M14.6%3 / 42 / 30M0M
Q4 20252810M14.6%1 / 33 / 00M0M
Q3 20252710M14.6%2 / 61 / 20M0M
Q2 20252810M14.6%26 / 00 / 07M0M
Q1 202533M4.2%1 / 00 / 10M0M
Q4 202443M4.2%0 / 00 / 50M12M
Q3 2024915M20.8%1 / 10 / 170M1M
Q2 20242616M22.8%2 / 26 / 20M0M
Q1 20242617M23.0%18 / 11 / 013M0M
Q4 202383M4.3%0 / 12 / 220M9M
Q3 20233012M16.5%1 / 31 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Yin WeidongChief Executive Officer, Director6,359,5008.85%Mar 18, 2026
Guang (Helen) YangChief Business Officer172,9000.24%Mar 18, 2026
Nan WangChief Financial Officer355,0000.49%Mar 18, 2026
Jing (Nmn) LiVP, Quality and Production227,5000.32%Mar 18, 2026
Qiang (Nmn) GaoChief Operation Officer230,0000.32%Mar 18, 2026
Jiaqiang LiDirector18,515,31525.77%Apr 17, 2026
Yuk Lam LoDirector90,0000.13%Mar 18, 2026
Simon AndersonDirector70,0000.10%Mar 18, 2026
Yu Min QiuDirector––Mar 18, 2026
Shan FuDirector5,903,0008.21%Mar 18, 2026
Shuge JiaoDirector––Mar 18, 2026
Yu (Nmn) WangDirector––Mar 18, 2026
Andrew Y. YanDirector10,780,82015.00%Mar 18, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.33%
0M shares short
Days to cover
1000.0
Change since last report
0.0%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Sinovac Biotech's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?